多发性硬化症新药Tecfidera的药理与临床研究

Pharmacological and clinical study of Tecfidera,a new treatment for multiple sclerosis

富马酸二甲酯(BG-12)于2013年被美国FDA批准用于治疗成人复发型多发性硬化症(multiple sclerosis,MS),可能通过细胞保护和抗炎作用在复发缓解型多发性硬化症患者中发挥疗效。本文通过文献检索,对其药理作用、药动学、药物相互作用、临床研究和安全性进行了综述。

Dimethyl fumarate （BG-12） is an oral agent approved by US Food and Drug Administration for patients with relapsing forms of multiple sclerosis in 2013. BG-12 may have cytoprotective and anti- inflammatory properties that contribute to its efficacy in patients with relapsing-remitting multiple sclerosis. A literature search was conducted using MEDLINE. The pharmacology, pharmacokinetics and drug interactions, key efficacy and safety from clinical studies were reviewed in this paper.